Regulation & Industry

Leading European patent litigator to join Carpmaels & Ransford
18 September 2026   The new hire brings more than two decades’ experience managing complex cross-border disputes in life sciences and technology, including most recently at the Unified Patent Court.

More News

27 August 2026   Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.
25 August 2026   While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.
24 August 2026   Labour MP for Stockton North takes up a new role as Minister for Science, Innovation and Investment within Andy Burnham’s government.
12 August 2026   Unified Patent Court judge Margot Kokke has had an unconventional and oft-interrupted career as the “trailing spouse” of a diplomat. She talks to Sarah Speight about this and more in the fourth in a series of interviews with women judges at the court.
7 August 2026   A federal judge has refused to disqualify Kirkland & Ellis from representing a healthcare tech company after a conflict check came under scrutiny.
7 August 2026   After more than 14 years at the US International Trade Commission, the new hire says he was drawn to Mintz for its “continued growth in the life sciences sector”.
5 August 2026   From advising pioneering startups to championing women in the profession, Fran Salisbury of Mewburn Ellis has spent her career making innovation count. Here, she reflects on the challenges, opportunities and motivations that continue to drive her.
More news


Latest Features

Pharma
A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
All features